The changing face of migraine

Current Pain and Headache Reports

Volumn 8, Issue 2, 2004, Pages 85-90

  Potrebic, Sonia ^a  

^a KAISER PERMANENTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALMOTRIPTAN; AMITRIPTYLINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIMIGRAINE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; ELETRIPTAN; FROVATRIPTAN; NARATRIPTAN; NOSE SPRAY; PROPRANOLOL; PROTEIN C FOS; RIZATRIPTAN; SEROTONIN ANTAGONIST; SUMATRIPTAN; TIMOLOL; TOPIRAMATE; VALPROATE SEMISODIUM; ZOLMITRIPTAN;

BRAIN BLOOD FLOW; BRAIN STEM RESPONSE; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE CLASSIFICATION; DORSAL RAPHE NUCLEUS; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG FORMULATION; DRUG INDICATION; DRUG SAFETY; HUMAN; MEDICAL CARE; MIGRAINE; NERVE CELL EXCITABILITY; NEUROBIOLOGY; PERIAQUEDUCTAL GRAY MATTER; PROTEIN EXPRESSION; REVIEW; SENSITIZATION; SEROTONINERGIC NERVE CELL; SIDE EFFECT; SUPPOSITORY; TABLET FORMULATION; TRIGEMINAL NUCLEUS; PRACTICE GUIDELINE;

HUMANS; MIGRAINE DISORDERS; PRACTICE GUIDELINES;

EID: 2342507641     PISSN: 15313433     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11916-004-0021-0     Document Type: Review

References (49)

1. Maetzel A, Li L: The economic burden of low back pain: a review of studies published between 1996 and 2001. Best Pract Res Clin Rheumatol 2002, 16:23-30.
2. Pop PH, Gierveld CM, Karis HA, Tiedink HG: Epidemiological aspects of headache in a workplace setting and the impact on the economic loss. Eur J Neurol 2002, 9:171-174.
3. Hu XH, Markson LE, Lipton RB, et al.: Burden of migraine in the United States: disability and economic costs. Arch Intern Med 1999, 159:813-818.
4. Lanteri-Minet M, Auray JP, El Hasnaui A, et al.: Prevalence and description of chronic daily headache in the general population of France. Pain 2003, 102:143-149.
5. Castillo J, Munoz F, Guitera V, Pasual J: Epidemiology of chronic daily headache in the general population. Headache 1998, 39:190-196.
6. Headache Classification Subcommittee of the International Headache Society: Classification and diagnostic criteria for headache disorders, cranial neuralgias, and facial pain. Cephalalgia 1988, 8:1-93.
7. Rasmussen BK, Jensen R, Olesen J: A population-based analysis of the diagnostic criteria of the International Headache Society. Cephalalgia 1991, 11:129-134.
8. Lipton RB, Cady RK, Stewart WF, et al.: Diagnostic lessons from the spectrum study. Neurology 2002, 58:S27-S31.
9. Lipton RB, Diamond S, Reed M, et al.: Migraine diagnosis and treatment: results from the American Headache Study II. Headache 2001, 41:638-645.
10. Lipton RB, Bigal ME, Kolodner K, et al.: The family impact of migraine: population based studies in the USA and UK. Cephalalgia 2003, 23:429-440.
11. Headache Classification Subcommittee of the International Headache Society: The international classification of headache disorders, edn 2. http://www.i-h-s.org.
12. Mathew NT, Stubits E, Nigam MP: Transformation of episodic migraine into daily headache: analysis of factors. Headache 1982, 22:66-68.
13. Limmroth V, Katsarava Z, Fritsche G, et al.: Features of medication overuse headache following overuse of different acute headache drugs. Neurology 2002, 59:1011-1014.
14. Wang SJ, Fuh JL, Lu SR, et al.: Chronic daily headache in Chinese elderly. Neurology 2000, 54:314-319.
15. Silberstein SD, Lipton RB, Solomon S, Mathew N: Classification of daily and near-daily headaches: proposed revisions to the IHS criteria. Headache 1994, 34:1-7.
16. Diamond ML: The role of concomitant headache types and non-headache comorbidities in the underdiagnosis of migraine. Neurology 2002, 58:S3-S9.
17. Cady RK, Schreiber CP: Sinus headache or migraine? Considerations in making a differential diagnosis. Neurology 2002, 58:S10-S14.
18. Lipton RB, Stewart WF, Cady RK, et al.: Sumatriptan for the range of headache in migraine sufferers: results of the spectrum study. Headache 2000, 40:783-791.
19. Brennum J, Schriver L, Wanscher B, et al.: Sumatriptan has no clinically significant effect in the treatment of episodic tension type headache. Eur J Neurol 1996, 3:23-28.
20. Silberstein S: Practice parameter: evidenced-based guidelines for migraine headache (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000, 55:754-762.
21. Goadsby PJ, Lipton RB, Ferrari MD: Migraine: current understanding and treatment. N Engl J Med 2002, 346:257-270.
22. Matchar DB, Young WB, Rosenberg JH, et al.: Evidenced-based guidelines for migraine headache in the primary care setting: pharmacological management of acute attacks. http://www.aan.com 2000. Accessed November 1, 2003.
23. Lipton RB, Stewart WF, Stone AM, et al.: Stratified care vs step care strategies for migraine: the Disabilities in Strategies of Care Study group. JAMA 2002, 284:2599-2605.
24. Sculpher M, Millson D, Meddis D, Poole L: Cost-effectiveness analysis of stratified versus stepped care strategies for acute treatment of migraine: the Disability in Strategies for Care (DISC) Study. Pharmacoeconomics 2002, 20:91-100.
25. Maizels M, Saenz V, Wirjo J: Impact of a group-based model of disease management for headache. Headache 2003, 43:621-627.
26. Tfelt-Hansen P: Efficacy and adverse events of subcutaneous, oral, and intranasal sumatriptan used for migraine treatment: a systematic review based on number needed to treat. Cephalalgia 1998, 18:532-538.
27. Boyle R, Behan PO, Sutton JA: A correlation between severity of migraine and delayed gastric emptying measured by an epigastric impedance method. Br J Clin Pharmacol 1990, 30:405-409.
28. Package-Insert: Maxalt(rizatriptan benzoate) tablets and Maxalt-MLT (rizatriptan benzoate) orally disintegrating tablets. West Point, PA: Merck and Co, Inc; October 1998.
29. Ferrari MD, Roon KI, Lipton RB, Goadsby PJ: Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 2001, 358:1668-1675.
30. Cady RK, Lipton RB, Hall C, et al.: Treatment of mild headache in disabled migraine sufferers: results from the spectrum study. Headache 2000, 40:792-797.
31. Farkkila M, Olesen J, Dahlof C, et al.: Eletriptan in the treatment of migraine in patients with previous poor response to tolerance to oral sumatriptan. Cephalalgia 2003, 23:463-471.
32. Stark R, Spierings EL, McNeal S, et al.: Efficacy of naratriptan tablets in those who respond poorly to oral sumatriptan. Headache 2000, 40:513-520.
33. Ramadan NM, Silberstein S, Freitag FG, et al.: Evidence-based guidelines for migraine headache in the primary care setting: pharmacological management for the prevention of migraine. http://www.aan.com 2000. Accessed November 1, 2003.
34. Weiller C, May A, Limmroth V, et al.: Brain stem activation in spontaneous human migraine attacks. Nat Med 1995, 1:658-660.
35. Welch KM, Nagesh V, Aurora SK: Periaqueductal gray matter dysfunction in migraine: Cause or the burden of illness? Headache 2001, 41:629-637.
36. Raskin NH, Hosobuchi Y, Lamb S: Headache may arise from perturbation of brain. Headache 1987, 27:416-420.
37. Ambrosini A, de Noordhout A, Sandor PS, Schoenen J: Electrophysiological studies in migraine: a comprehensive view of their interest and limitations. Cephalalgia 2003, 23:13-31.
38. Valeriani M, de Tommaso M, Restuccia D, et al.: Reduced habituation to experimental pain in migraine patients: a CO(2) laser-evoked potential study. Pain 2003, 105:57-64.
39. Wray SH, Mijovic-Prelec D, Kosslyn SM: Visual processing in migraineurs. Brain 1995, 118:25-35.
40. Aurora SK, Ahmad BK, Welch KM, et al.: Transcranial magnetic stimulation confirms hyperexcitability of occipital cortex in migraine. Neurology 1998, 50:1111-1114.
41. Mayexsky A, Doron A, Manor T et al.: Cortical spreading depression form the human brain using a multiparametric monitoring system. Brain Res 1996, 740:268-272.
42. Hadjikhani N, Sanchez Del Rio M, et al.: Mechanisms of migraine aura revealed by functional MRI in human visual cortex. Proc Natl Acad Sci U S A 2001, 98:4687-4692.
43. Woods RP, Iacoboni M, Mazziotta JC: Brief report: bilateral spreading cerebral hypoperfusion during spontaneous migraine headache. N Engl J Med 1994, 331:1689-1692.
44. Bolay H, Reuter U, Dunn AK, et al.: Intrinsic brain activity triggers trigerninal meningeal afferents in a migraine model. Nat Med 2002, 8:136-142.
45. Strassman AM, Raymond SA, Burstein R: Sensitization of meningeal sensory neurons and the origin of headaches. Nature 1996, 384:560-564.
46. Burstein R: Deconstructing migraine headache into peripheral and central sensitization. Pain 2001, 89:107-110.
47. Burstein R, Yamamura H, Malick A, Strassman AM: Chemical stimulation of the intracranial dura induces enhanced responses to facial stimulation in brain stem trigeminal neurons. J Neurophysiol 1998, 79:964-982.
48. Burstein R, Yarnitsky D, Goor-Aryeh I, et al.: An association between migraine and cutaneous allodynia. Ann Neurol 2000, 47:614-624.
49. Burstein R, Collins B, Bajwa ZH, Jakubowski M: Triptan therapy can abort migraine attacks if given before the establishment or in the absence of cutaneous allodynia and central sensitization: clinical and preclinical evidence [Abstract]. Headache 2002, 42:390.